Clinical trials: Malignancies Multiple
Chronic Lymphocytic Leukemia (CLL), Lymphoma, Non-Hodgkin (NHL)
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
The purpose of this study is to determine the dose that can be safely given to see what effect it may have on your cancer and to determine how the drug is distributed in the body.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Lymphoma, Non-Hodgkin (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM)
- Trial name
- NCT00710528
- Testing
- CAL-101
- Where
- 9 sites in United States
- Volunteers
- 192 people
- Sponsor
- Gilead Sciences
Malignant Melanoma
4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy
Phase Ib/II open-label, multi-center study with a priming cycle of 4SC-202 to evaluate the safety, tolerability and preliminary efficacy of combination treatment with 4SC-202 and Pembrolizumab.
- Trial name
- SENSITIZE (NCT03278665)
- Testing
- 4SC-202 in combination with Pembrolizumab
- Where
- 7 sites in Germany, Italy
- Volunteers
- 40 people
- Sponsor
- 4SC AG
Acute Leukemia, Chronic Leukemia
Fungemia in Hematologic Malignancies
The purpose of this study is to determine the risk factors for fungemia in a population of patients diagnosed with hematologic malignancies and eligible for chemotherapy.
- Conditions
- Acute Leukemia, Chronic Leukemia, Multiple Myeloma, Lymphoma
- Trial name
- NCT02451592
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne
Endometrial Cancer, Cancer Screening
DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening
Based on the previous study of NCT04651738, we performed this trial to further confirm the accuracy of host DNA CDO1 and CELF4 methylation for endometrial cancer screening.
- Conditions
- Endometrial Cancer, Cancer Screening, DNA Methylation, Testing Accuracy
- Trial name
- NCT05290922
- Testing
- DNA methylation testing
- Where
- China
- Volunteers
- 7,150 people
- Sponsor
- Lei Li
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
- Trial name
- NCT05544929
- Testing
- KFA115, pembrolizumab
- Where
- 18 sites in United States, Canada and 10 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Seroma, Aspiration
Seroma Reduction After Mastectomy
Rationale: Seroma formation and its sequelae form the mainstay of complications in breast cancer surgery. Seroma has an incidence of 3% to 85%.
- Conditions
- Seroma, Aspiration, Breast Cancer
- Trial name
- SAM (NCT03305757)
- Testing
- Artiss, vicryl sutures, Conventional
- Where
- Netherlands
- Volunteers
- 339 people
- Sponsor
- Zuyderland Medisch Centrum
Small-cell Lung Cancer
Watchful Observation of Patients With LD-SCLC Instead of the PCI
Prophylactic cranial irradiation (PCI) is a current standard of care after confirmed response to radical chemoradiotherapy for limited disease small cell lung cancer (LD-SCLC).
- Trial name
- PCILESS (NCT04168281)
- Testing
- Magnetic resonance imaging (MRI)
- Where
- Poland
- Volunteers
- 80 people
- Sponsor
- Sergiusz Nawrocki
Diffuse Large B-cell Lymphoma
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
In the current protocol version, there are two parts. Part I is a pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in…
- Trial name
- DALY 2-EU (NCT04844866)
- Testing
- MB-CART2019.1, Standard of Care
- Where
- 51 sites in Austria, Belgium and 12 more
- Volunteers
- 213 people
- Sponsor
- Miltenyi Biomedicine GmbH
Multiple Myeloma
Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
This is a multicenter, open label clinical trial evaluating the safety of the combination of belantamab mafodotin + the combination treatment VRd (bortezomib, lenalidomide, dexamethasone) in newly diagnosed (ND) transplant…
- Trial name
- NCT04802356
- Testing
- Belantamab mafodotin, Bortezomib, Lenalidomide
- Where
- 12 sites in Spain
- Volunteers
- 50 people
- Sponsor
- PETHEMA Foundation
Phase 2, Radiotherapy-Induced Immune Priming
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.
- Conditions
- Phase 2, Radiotherapy-Induced Immune Priming, Elranatamab, Relapsed Refractory Multiple Myeloma (RRMM)
- Trial name
- NCT07382739
- Testing
- Elranatamab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed Cancer, Refractory Multiple Myeloma
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
The main goal of this phase II study is to evaluate the overall response rate of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
- Conditions
- Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma
- Trial name
- ISABELA (NCT05922501)
- Testing
- Isatuximab, Belantamab mafodotin, Pomalidomide
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Tuberous Sclerosis, Neurofibromatoses
Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)
This study is a prospective, randomized, double-blind, placebo-controlled evaluation of the safety of a topically applied formulation of rapamycin to cutaneous fibromatous lesions in subjects with Tuberous Sclerosis Complex (TSC)…
- Conditions
- Tuberous Sclerosis, Neurofibromatoses, Angiofibroma, Neurofibroma
- Trial name
- NCT01031901
- Testing
- Skincerity, Skincerity plus sirolimus/rapamycin, Skinercity plus sirolimus/rapamycin
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Head and Neck Neoplasms, Carcinoma, Squamous Cell
Postoperative Concurrent Chemoradiation for Head and Neck Cancer With Multiple Minor Risk
The purpose of this study is to determine the treatment outcome of postoperative concurrent chemoradiation for head and neck squamous cell carcinoma with multiple minor risks.
- Trial name
- NCT00937612
- Testing
- Radiotherapy
- Where
- 3 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- Chang Gung Memorial Hospital
Colorectal Cancer
Multi-scale Spatio-Temporal Analysis of Research Data
MuSTARD is a singular project in the sense that investigators will develop a computational framework that is conceived as a common solution for disparate applications.
- Trial name
- MuSTARD (NCT07189312)
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Universidad de Granada
Urinary Incontinence
Clinical Study of External Electrical Stimulation for Male Incontinence
The purpose of this research is to evaluate the effectiveness of the Elidah neuromuscular stimulation treatment to reduce incontinence in men post-prostatectomy.
- Trial name
- NCT06620419
- Testing
- Perineal-applied electrical stimulation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Elidah, Inc.
Melanoma
Randomised Study to Compare the Efficacy of AZD6244 vs TMZ
The primary purpose of this study is to compare the efficacy of AZD6244 (ARRY-142886) with temozolomide in patients with advanced melanoma
- Trial name
- NCT00338130
- Testing
- AZD6244, Temozolomide
- Where
- 33 sites in United States, Argentina and 8 more
- Volunteers
- 239 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)
The goal of this clinical trial is to compare therapeutic drug monitoring (TDM) versus Standard of care in patients with rheumatoid arthritis treated with a subcutaneous tumor necrosis factor inhibitor (adalimumab).
- Trial name
- RA-DRUM (NCT06440629)
- Testing
- Therapeutic drug monitoring (TDM) of adalimumab
- Where
- 22 sites in Austria, Italy and 4 more
- Volunteers
- 387 people
- Sponsor
- Diakonhjemmet Hospital
Early Detection of Cancer
Understanding Information Preferences, Risk Perceptions, and Tradeoffs When Making Decisions About Multi-cancer Early Detection Tests
The goal of this clinical trial is to learn what people's informational preferences and risk perceptions are in regards to the use of multi-cancer early detection (MCED) tests.
- Trial name
- NCT07793539
- Testing
- Test Performance Information: High Detail, Test Performance Information: Low Detail, Diagnostic Workup Information: High Detail
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- Trustees of Dartmouth College
Limited-stage Small Cell Lung Cancer (LS-SCLC)
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
This study aims to explore the efficacy and safety of immunotherapy (PD-L1 inhibitor) maintenance following high-dose hyperfractionated simultaneous integrated boost radiotherapy concurrent chemotherapy in patients with…
- Trial name
- NCT06869239
- Testing
- Etoposide + cisplatin/carboplatin, Thoracic radiotherapy, Prophylactic cranial irradiation (PCI)
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Peking University Cancer Hospital & Institute
Non-Small Cell Lung Cancer (NSCLC), Rehabilitation
Digital Rehabilitation With Wearable Monitors for Sequential Lung Cancer Resection
This is a prospective, open-label, parallel-group, 1:1 randomized controlled trial designed to evaluate whether a digital rehabilitation program integrated with wireless wearable continuous monitoring devices can shorten the time…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Rehabilitation, Thoracic Surgery
- Trial name
- WEAR-MPLC (NCT07797075)
- Testing
- Wireless Wearable Vital Sign and Activity Monitor, Digital Pulmonary Rehabilitation Program, Standard ERAS Perioperative and Rehabilitation Care
- Where
- China
- Volunteers
- 222 people
- Sponsor
- West China Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.